Ray Therapeutics (RayTx) is a clinical-stage biotechnology company pioneering optogenetic gene therapies for blinding retinal diseases. RayTx aims to provide best-in-class and first-in-class, mutation-agnostic, vision restoration to patients without available treatment options. Founded in 2021 and headquartered in Berkeley, CA, the company raised $100 million in a Series A financing led by Novo Holdings in May 2023.
RayTx’s lead asset, RTx-015, delivers a highly bioengineered light-sensitive protein, and is currently in phase 1/2 clinical trials, initially for retinitis pigmentosa (RP). RayTx’s second asset, RTx-021, is expected to enter clinical trials in 2025 for Stargardt macular dystrophy (STGD) and geographic atrophy age related macular degeneration (GA AMD).
The Head of Clinical Operations is a crucial leadership role responsible for overseeing and directing all aspects of clinical operation and must balance strategic vision with hands-on operational management to drive the organization’s clinical research initiatives forward. This role is critical in ensuring the successful execution of clinical trials, advancing drug development efforts, and ultimately contributing to improved patient outcomes. This position requires a combination of strategic vision, operational expertise, and clinical knowledge. The successful applicant will report to the Chief Medical Officer.
The role is based in our Berkeley, CA office with a hybrid work from home/in office requirement and will require travel to our clinical trial sites, efficacy testing facilities, conferences and other travel, as required.